Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...

Panel A shows the changes in the levels of the bone-formation marker procollagen type 1 N-terminal propeptide (P1NP) and the levels of the bone-resorption marker C-terminal telopeptide (CTX) in each ...

Patients who discontinue treatment with the osteoporosis drug denosumab, despite transitioning to zoledronate, show significant losses in lumbar spine bone mineral density (BMD) within a year, ...

Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...